Severe acute respiratory syndrome and coronavirus

Infectious Disease Clinics of North America

Volumn 24, Issue 3, 2010, Pages 619-638

  Hui, David S C ^a   Chan, Paul K S ^a  

^a CHINESE UNIVERSITY OF HONG KONG   (Hong Kong)

Author keywords

Clinical features; Outcome; Pathogenesis; SARS; Treatment

Indexed keywords

ALPHA INTERFERON; ALPHA1 INTERFERON; AMINOTRANSFERASE; ANGIOTENSIN CONVERTING ENZYME 2; ANTIBIOTIC AGENT; BETA INTERFERON; BETA1A INTERFERON; CHINESE DRUG; CORTICOSTEROID; DNA VACCINE; GAMMA INTERFERON; GLYCYRRHIZIC ACID; HUMAN MONOCLONAL ANTIBODY; HUMAN MONOCLONAL ANTIBODY 80R; HYDROCORTISONE; IMMUNOGLOBULIN; IMMUNOGLOBULIN G; LOPINAVIR; LOPINAVIR PLUS RITONAVIR; LOW MOLECULAR WEIGHT HEPARIN; METHYLPREDNISOLONE; NELFINAVIR; NITRIC OXIDE; OSELTAMIVIR; PEGINTERFERON ALPHA; PLACEBO; PROTEINASE INHIBITOR; RIBAVIRIN; SEVERE ACUTE RESPIRATORY SYNDROME VACCINE; UNCLASSIFIED DRUG; UNINDEXED DRUG; ANTIVIRUS AGENT; IMMUNOLOGIC FACTOR;

ADULT RESPIRATORY DISTRESS SYNDROME; ARTERY THROMBOSIS; ARTIFICIAL VENTILATION; BLOOD VISCOSITY; BRADYCARDIA; CLINICAL FEATURE; CLINICAL TRIAL; CORONAVIRUS; DISEASE SEVERITY; DRUG BLOOD LEVEL; DRUG MEGADOSE; DRUG POTENTIATION; EPIDEMIC; HIGH RESOLUTION COMPUTER TOMOGRAPHY; HOSPITAL INFECTION; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNOBIOLOGY; INCIDENCE; INFLUENZA; LABORATORY TEST; LUNG ARTERY THROMBOSIS; LUNG EMBOLISM; MONOTHERAPY; MORTALITY; NONHUMAN; PATHOGENESIS; RESPIRATORY FAILURE; RESPIRATORY TRACT DISEASE; REVIEW; SARS CORONAVIRUS; SECONDARY INFECTION; SEROPREVALENCE; SEVERE ACUTE RESPIRATORY SYNDROME; SIDE EFFECT; SYMPTOM; VACCINE PRODUCTION; VENOUS THROMBOEMBOLISM; VIRAL CONTAMINATION; VIRAL UPPER RESPIRATORY TRACT INFECTION; VIREMIA; VIRUS ENTRY; VIRUS LOAD; VIRUS PNEUMONIA; VIRUS REPLICATION; VIRUS STRAIN; VIRUS TRANSMISSION; ANIMAL; CASE REPORT; CLASSIFICATION; COMMUNICABLE DISEASES, EMERGING; IMMUNOTHERAPY; ISOLATION AND PURIFICATION; MALE; MIDDLE AGED; PROCEDURES; VIROLOGY;

ANIMALS; ANTIVIRAL AGENTS; COMMUNICABLE DISEASES, EMERGING; DISEASE OUTBREAKS; HUMANS; IMMUNOLOGIC FACTORS; IMMUNOTHERAPY; MALE; MIDDLE AGED; SARS VIRUS; SEVERE ACUTE RESPIRATORY SYNDROME;

EID: 77955300372     PISSN: 08915520     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.idc.2010.04.009     Document Type: Review

References (169)

1. Lee N., Hui D.S., Wu A., et al. A major outbreak of severe acute respiratory syndrome in Hong Kong. N Engl J Med 2003, 348:1986-1994.
2. Hsu L.Y., Lee C.C., Green J.A., et al. Severe acute respiratory syndrome in Singapore: clinical features of index patient and initial contacts. Emerg Infect Dis 2003, 9:713-717.
3. Booth C.M., Matukas L.M., Tomlinson G.A., et al. Clinical features and short-term outcomes of 144 patients with SARS in the greater Toronto area. JAMA 2003, 289:2801-2809.
4. Twu S.J., Chen T.J., Chen C.J., et al. Control measures for severe acute respiratory syndrome (SARS) in Taiwan. Emerg Infect Dis 2003, 9:718-720.
5. WHO Summary of probable SARS cases with onset of illness from 1 November to 31 July 2003 Available at:, Accessed September 23, 2003. http://www.who.int/csr/sars/country/table2003_09_23/en.
6. Wang M., Yan M., Xu H., et al. SARS-CoV infection in a restaurant from palm civet. Emerg Infect Dis 2005, 11:1860-1865.
7. Che X.Y., Di B., Zhao G.P., et al. A patient with asymptomatic severe acute respiratory syndrome (SARS) and antigenemia from the 2003-2004 community outbreak of SARS in Guangzhou, China. Clin Infect Dis 2006, 43:e1-e5.
8. Peiris J.S., Lai S.T., Poon L.L., et al. Coronavirus as a possible cause of severe acute respiratory syndrome. Lancet 2003, 361:1319-1325.
9. Kuiken T., Fouchier R.A., Schutten M., et al. Newly discovered coronavirus as the primary cause of severe acute respiratory syndrome. Lancet 2003, 362:263-270.
10. Drosten C., Gunther S., Preiser W., et al. Identification of a novel Coronavirus in patients with severe acute respiratory syndrome. N Engl J Med 2003, 348:1967-1976.
11. Ksiazek T.G., Erdman D., Goldsmith C.S., et al. A novel Coronavirus associated with severe acute respiratory syndrome. N Engl J Med 2003, 348:1953-1966.
12. Fouchier R.A., Kuiken T., Schutten M., et al. Aetiology: Koch's postulates fulfilled for SARS virus. Nature 2003, 423:240.
13. Rota P.A., Oberste M.S., Monroe S.S., et al. Characterization of a novel coronavirus associated with severe acute respiratory syndrome. Science 2003, 300:1394-1399.
14. Marra M.A., Jones S.J., Astell C.R., et al. The genome sequence of the SARS-associated coronavirus. Science 2003, 300:1399-1404.
15. Ruan Y.J., Wei C.L., Ee L.A., et al. Comparative full-length genome sequence analysis of 14 SARS coronavirus isolates and common mutations associated with putative origins of infection. Lancet 2003, 361:1779-1785.
16. Du L., Qiu J.C., Wang M., et al. Analysis on the characteristics of blood serum Ab-IgG detective result of severe acute respiratory syndrome patients in Guangzhou, China. Zhonghua Liu Xing Bing Xue Za Zhi 2004, 25:925-928.
17. Guan Y., Zheng B.J., He Y.Q., et al. Isolation and characterization of viruses related to the SARS coronavirus from animals in Southern China. Science 2003, 302:276-278.
18. Song H.D., Tu C.C., Zhang, et al. Cross-host evolution of severe acute respiratory syndrome coronavirus in palm civet and human. Proc Natl Acad Sci U S A 2005, 102:2430-2435.
19. Lau S.K., Woo P.C., Li K.S., et al. Severe acute respiratory syndrome coronavirus-like virus in Chinese horseshoe bats. Proc Natl Acad Sci U S A 2005, 102:14040-14045.
20. Li W., Shi Z., Yu M., et al. Bats are natural reservoirs of SARS-like coronaviruses. Science 2005, 310:676-679.
21. Shi Z., Hu Z. A review of studies on animal reservoirs of the SARS coronavirus. Virus Res 2008, 133:74-87.
22. Zhao Z., Zhang F., Xu M., et al. Description and clinical treatment of an early outbreak of severe acute respiratory syndrome (SARS) in Guangzhou, PR China. J Med Microbiol 2003, 52:715-720.
23. Xu R.H., He J.F., Evans M.R., et al. Epidemiologic clues to SARS origin in China. Emerg Infect Dis 2004, 10:1030-1037.
24. Zhong N.S., Zheng B.J., Li Y.M., et al. Epidemiology and cause of severe acute respiratory syndrome in Guangdong, People's Republic of China, in 2003. Lancet 2003, 362:1353-1358.
25. Tsang K.W., Ho P.L., Ooi G.C., et al. A cluster of cases of severe acute respiratory syndrome in Hong Kong. N Engl J Med 2003, 348:1977-1985.
26. Peiris J.S., Yuen K.Y., Osterhaus A.D., et al. The severe acute respiratory syndrome. N Engl J Med 2003, 349:2431-2441.
27. Wong R.S., Hui D.S. Index patient and SARS outbreak in Hong Kong. Emerg Infect Dis 2004, 10:339-341.
28. Loon S.C., Teoh S.C., Oon L.L., et al. The severe acute respiratory syndrome coronavirus in tears. Br J Ophthalmol 2004, 88:861-863.
29. Yu I.T., Li Y., Wong T.W., et al. Evidence of airborne transmission of the severe acute respiratory syndrome virus. N Engl J Med 2004, 350:1731-1739.
30. Chu C.M., Cheng V.C., Hung I.F., et al. Viral load distribution in SARS outbreak. Emerg Infect Dis 2005, 11:1882-1886.
31. Booth T.F., Kournikakis B., Bastien N., et al. Detection of airborne severe acute respiratory syndrome (SARS) coronavirus and environmental contamination in SARS outbreak units. J Infect Dis 2005, 191:1472-1477.
32. Yu I.T., Wong T.W., Chiu Y.L., et al. Temporal-spatial analysis of severe acute respiratory syndrome among hospital inpatients. Clin Infect Dis 2005, 40:1237-1243.
33. Leung G.M., Hedley A.J., Ho L.M., et al. The epidemiology of severe acute respiratory syndrome in the 2003 Hong Kong epidemic: an analysis of all 1755 patients. Ann Intern Med 2004, 141:662-673.
34. Hui D.S., Wong P.C., Wang C. Severe acute respiratory syndrome: clinical features and diagnosis. Respirology 2003, 8:S20-S24.
35. Peiris J.S., Chu C.M., Cheng V.C., et al. Clinical progression and viral load in a community outbreak of coronavirus-associated SARS pneumonia: a prospective study. Lancet 2003, 361:1767-1772.
36. Leung W.K., To K.F., Chan P.K., et al. Enteric involvement of severe acute respiratory syndrome-associated coronavirus infection. Gastroenterologist 2003, 125:1011-1017.
37. Chan H.L., Kwan A.C., To K.F., et al. Clinical significance of hepatic derangement in severe acute respiratory syndrome. World J Gastroenterol 2005, 11:2148-2153.
38. Hung E.C., Chim S.S., Chan P.K., et al. Detection of SARS coronavirus RNA in the cerebrospinal fluid of a patient with severe acute respiratory syndrome. Clin Chem 2003, 49:2108-2109.
39. Lau K.K., Yu W.C., Chu C.M., et al. Possible central nervous system infection by SARS coronavirus. Emerg Infect Dis 2004, 10:342-344.
40. Wong K.C., Leung K.S., Hui M. Severe acute respiratory syndrome (SARS) in a geriatric patient with a hip fracture. A case report. J Bone Joint Surg Am 2003, 85:1339-1342.
41. Lee A.K., Oh H.M., Hui K.P., et al. Atypical SARS in a geriatric patient. Emerg Infect Dis 2004, 10:261-264.
42. Fisher D.A., Lim T.K., Lim Y.T., et al. Atypical presentations of SARS. Lancet 2003, 361:1740.
43. Hon K.L., Leung C.W., Cheng W.T., et al. Clinical presentations and outcome of severe acute respiratory syndrome in children. Lancet 2003, 561:1701-1703.
44. Sit S.C., Yau E.K.C., Lam Y.Y., et al. A young infant with severe acute respiratory syndrome. Pediatrics 2003, 112:e257-e260.
45. Bitnun A., Allen U., Heurter H., et al. Children hospitalized with severe acute respiratory syndrome-related illness in Toronto. Pediatrics 2003, 112:e261-e268.
46. Chiu W.K., Cheung P.C., Ng K.L., et al. Severe acute respiratory syndrome in children: experience in a regional hospital in Hong Kong. Pediatr Crit Care Med 2003, 4:279-283.
47. Wong S.F., Chow K.M., Leung T.N., et al. Pregnancy and perinatal outcomes of women with severe acute respiratory syndrome. Am J Obstet Gynecol 2004, 191:292-297.
48. Xu J.L., Qi X., Chi J., et al. Orchitis: a complication of severe acute respiratory syndrome (SARS). Biol Reprod 2006, 74:410-416.
49. Leung G.M., Lim W.W., Ho L.M., et al. Seroprevalence of IgG antibodies to SARS-coronavirus in asymptomatic or subclinical population groups. Epidemiol Infect 2006, 134:211-221.
50. Yu I.T., Xie Z.H., Tsoi K.K., et al. Why did outbreaks of severe acute respiratory syndrome occur in some hospital wards but not in others?. Clin Infect Dis 2007, 44:1017-1025.
51. Hui D.S., Hall S.D., Chan M.T., et al. Exhaled air dispersion during oxygen delivery via a simple oxygen mask. Chest 2007, 132:540-546.
52. Hui D.S., Chow B.K., Hall S.D., et al. Exhaled air and aerosolized droplet dispersion during application of a jet nebulizer. Chest 2009, 135:648-654.
53. Hui D.S., Hall S.D., Chan M.T., et al. Non-invasive positive pressure ventilation: an experimental model to assess air and particle dispersion. Chest 2006, 130:730-740.
54. Hui D.S., Chow B.K., Hall S.D., et al. Exhaled air dispersion distances during application of non-invasive ventilation via different Respironics face masks. Chest 2009, 167:348-353.
55. Hui D.S., Wong K.T., Antonio G.E., et al. Severe acute respiratory syndrome (SARS): correlation of clinical outcome and radiological features. Radiology 2004, 233:579-585.
56. Hui D.S., Sung J.J. Severe acute respiratory syndrome. Chest 2003, 124:12-15.
57. Wong G.W., Hui D.S. Severe acute respiratory syndrome: epidemiology, diagnosis and treatment. Thorax 2003, 58:558-560.
58. Wong R.S., Wu A., To K.F., et al. Haematological manifestations in patients with severe acute respiratory syndrome: retrospective analysis. Br Med J 2003, 326:1358-1362.
59. Chen X., Zhou B., Li M., et al. Serology of severe acute respiratory syndrome: implications for surveillance and outcome. J Infect Dis 2004, 189:1158-1163.
60. Muller M.P., Tomlinson G., Marrie T.J., et al. Can routine laboratory tests discriminate between severe acute respiratory syndrome and other causes of community acquired pneumonia?. Clin Infect Dis 2005, 40:1079-1086.
61. Lee N., Rainer T.H., Ip M., et al. Role of laboratory variables in differentiating SARS-coronavirus from other causes of community-acquired pneumonia within the first 72 hrs of hospitalization. Eur J Clin Microbiol Infect Dis 2006, 25:765-772.
62. Rainer T.H., Lee N., Ip M., et al. Features discriminating SARS from other severe viral respiratory tract infections. Eur J Clin Microbiol Infect Dis 2007, 26:121-129.
63. Wong K.T., Antonio G.E., Hui D.S., et al. Severe acute respiratory syndrome: radiographic appearances and pattern of progression in 138 Patients. Radiology 2003, 228:401-406.
64. Gomersall C.D., Joynt G.M., Lam P., et al. Short-term outcome of critically ill patients with severe acute respiratory syndrome. Intensive Care Med 2004, 30:381-387.
65. Wong K.T., Antonio G.E., Hui D.S., et al. Thin section CT of severe acute respiratory syndrome: evaluation of 73 patients exposed to or with the disease. Radiology 2003, 228:395-400.
66. Chan P.K., To K.F., Lo A.W., et al. Persistent infection of SARS coronavirus in colonic cells in vitro. J Med Virol 2004, 74:1-7.
67. Simmons G., Gosalia D.N., Rennekamp A.J., et al. Inhibitors of cathepsin L prevent severe acute respiratory syndrome coronavirus entry. Proc Natl Acad Sci U S A 2005, 102:11876-11881.
68. Tripet B., Howard M.W., Jobling M., et al. Structural characterization of the SARS-coronavirus spike S fusion protein core. J Biol Chem 2004, 279:20836-20849.
69. Hofmann H., Pöhlmann S. Cellular entry of the SARS coronavirus. Trends Microbiol 2004, 12:466-472.
70. Li W., Moore M.J., Vasilieva N., et al. Angiotensin-converting enzyme 2 is a functional receptor for the SARS coronavirus. Nature 2003, 426:450-454.
71. Hamming I., Timens W., Bulthuis M.L., et al. Tissue distribution of ACE2 protein, the functional receptor for SARS coronavirus. A first step in understanding SARS pathogenesis. J Pathol 2004, 203:631-637.
72. Tang J.W., To K.F., Lo A.W., et al. Quantitative temporal-spatial distribution of severe acute respiratory syndrome-associated coronavirus (SARS-CoV) in post-mortem tissues. J Med Virol 2007, 79:1245-1253.
73. Yang Z.Y., Huang Y., Ganesh L., et al. pH-dependent entry of severe acute respiratory syndrome coronavirus is mediated by the spike glycoprotein and enhanced by dendritic cell transfer through DC-SIGN. J Virol 2004, 78:5642-5650.
74. Gramberg T., Hofmann H., Möller P., et al. LSECtin interacts with filovirus glycoproteins and the spike protein of SARS coronavirus. Virology 2005, 340:224-236.
75. van Kooyk Y., Geijtenbeek T.B. DC-SIGN: escape mechanism for pathogens. Nat Rev Immunol 2003, 3:697-709.
76. Jeffers S.A., Tusell S.M., Gillim-Ross L., et al. CD209L (L-SIGN) is a receptor for severe acute respiratory syndrome coronavirus. Proc Natl Acad Sci U S A 2004, 101:15748-15753.
77. Marzi A., Gramberg T., Simmons G., et al. DC-SIGN and DC-SIGNR interact with the glycoprotein of Marburg virus and the S protein of severe acute respiratory syndrome coronavirus. J Virol 2004, 78:12090-12095.
78. Lo A.W., Tang N.L., To K.F. How the SARS coronavirus causes disease: host or organism?. J Pathol 2006, 208:142-151.
79. Ng W.F., To K.F., Lam W.W., et al. The comparative pathology of severe acute respiratory syndrome and avian influenza A subtype H5N1-a review. Hum Pathol 2006, 37:381-390.
80. Gu J., Korteweg C. Pathology and pathogenesis of severe acute respiratory syndrome. Am J Pathol 2007, 170:1136-1147.
81. Cameron M.J., Bermejo-Martin J.F., Danesh A., et al. Human immunopathogenesis of severe acute respiratory syndrome (SARS). Virus Res 2007, 133:13-19.
82. Guo Y., Korteweg C., McNutt M.A., et al. Pathogenetic mechanisms of severe acute respiratory syndrome. Virus Res 2007, 133:4-12.
83. To K.F., Tong J.H., Chan P.K., et al. Tissue and cellular tropisms of the coronavirus associated with severe acute respiratory syndrome-an in-situ hybridization study of fatal cases. J Pathol 2004, 202:157-163.
84. Imai Y., Kuba K., Rao S., et al. Angiotensin-converting enzyme 2 protects from severe acute lung failure. Nature 2005, 436:112-116.
85. Burrell L.M., Johnston C.I., Tikellis C., et al. ACE2, a new regulator of the renin-angiotensin system. Trends Endocrinol Metab 2004, 15:166-169.
86. Wong S.L., Chen Y., Chan C.M., et al. In vivo functional characterization of the SARS-Coronavirus 3a protein in Drosophila. Biochem Biophys Res Commun 2005, 337:720-729.
87. Law P.T., Wong C.H., Au T.C., et al. The 3a protein of severe acute respiratory syndrome-associated coronavirus induces apoptosis in Vero E6 cells. J Gen Virol 2005, 86:1921-1930.
88. Tan Y.J., Fielding B.C., Goh P.Y., et al. Over expression of 7a, a protein specifically encoded by the severe acute respiratory syndrome coronavirus, induces apoptosis via a caspase-dependent pathway. J Virol 2004, 78:14043-14047.
89. Wong C.K., Lam C.W., Wu A.K., et al. Plasma inflammatory cytokines and chemokines in severe acute respiratory syndrome. Clin Exp Immunol 2004, 136:95-103.
90. Jiang Y., Xu J., Zhou C., et al. Characterization of cytokine/chemokine profiles of severe acute respiratory syndrome. Am J Respir Crit Care Med 2005, 171:850-857.
91. Huang K.J., Su I.J., Theron M., et al. An interferon-gamma-related cytokine storm in SARS patients. J Med Virol 2005, 75:185-194.
92. Tang N.L., Chan P.K., Wong C.K., et al. Early enhanced expression of IP-10 (CXCL-10) and other chemokines predict adverse outcome in severe acute respiratory syndrome (SARS). Clin Chem 2005, 51:2333-2340.
93. Zhang Y., Li J., Zhan Y., et al. Analysis of serum cytokines in patients with severe acute respiratory syndrome. Infect Immun 2004, 72:4410-4415.
94. Lau Y.L., Peiris J.S. Pathogenesis of severe acute respiratory syndrome. Curr Opin Immunol 2005, 17:404-410.
95. Lin M., Tseng H.K., Trejaut J.A., et al. Association of HLA class I with severe acute respiratory syndrome coronavirus infection. BMC Med Genet 2003, 4:9.
96. Ng M.H., Lau K.M., Li L., et al. Association of human-leukocyte-antigen class I (B*0703) and class II (DRB1*0301) genotypes with susceptibility and resistance to the development of severe acute respiratory syndrome. J Infect Dis 2004, 190:515-518.
97. Yuan F.F., Tanner J., Chan P.K., et al. Influence of FcγRIIA and MBL polymorphisms on severe acute respiratory syndrome. Tissue Antigens 2005, 66:291-296.
98. Yuan F.F., Boehm I., Chan P.K., et al. High prevalence of the CD14-159CC genotype in patients infected with severe acute respiratory syndrome-associated coronavirus. Clin Vaccine Immunol 2007, 14:1644-1645.
99. Ng M.W., Zhou G., Chong W.P., et al. The association of RANTES polymorphism with severe acute respiratory syndrome in Hong Kong and Beijing Chinese. BMC Infect Dis 2007, 7:50.
100. Chan V.S., Chan K.Y., Chen Y., et al. Homozygous L-SIGN (CLEC4M) plays a protective role in SARS coronavirus infection. Nat Genet 2006, 38:38-46.
101. Tang N.L., Chan P.K., Hui D.S., et al. Lack of support for an association between CLEC4M homozygosity and protection against SARS coronavirus infection. Nat Genet 2007, 39:691-692.
102. Zhi L., Zhou G., Zhang H., et al. Lack of support for an association between CLEC4M homozygosity and protection against SARS coronavirus infection. Nat Genet 2007, 39:692-694.
103. Cinatl J., Morgenstern B., Bauer G., et al. Glycyrrhizin, an active component of liquorice roots, and replication of SARS-associated coronavirus. Lancet 2003, 361:2045-2046.
104. Tan E.L., Ooi E.E., Lin C.Y., et al. Inhibition of SARS coronavirus infection in vitro with clinically approved antiviral drugs. Emerg Infect Dis 2004, 10:581-586.
105. Stroher U., DiCaro A., Li Y., et al. Severe acute respiratory syndrome-related coronavirus is inhibited by interferon-α. J Infect Dis 2004, 189:1164-1167.
106. Sung J.J., Wu A., Joynt G.M., et al. Severe acute respiratory syndrome: report of treatment and outcome after a major outbreak. Thorax 2004, 59:414-420.
107. Ng E.K., Ng P.C., Hon K.L., et al. Serial analysis of the plasma concentration of SARS coronavirus RNA in pediatric patients with severe acute respiratory syndrome. Clin Chem 2003, 49:2085-2088.
108. Anand K., Ziebuhr J., Wadhwani P., et al. Coronavirus main proteinase (3Clpro) structure: basis for design of anti-SARS drugs. Science 2003, 300:1763-1767.
109. Chu C.M., Cheng V.C., Hung I.F., et al. Role of lopinavir/ritonavir in the treatment of SARS: initial virological and clinical findings. Thorax 2004, 59:252-256.
110. Chan K.S., Lai S.T., Chu C.M., et al. Treatment of severe acute respiratory syndrome with lopinavir/ritonavir: a multicenter retrospective matched cohort study. Hong Kong Med J 2003, 9:399-406.
111. Hurst M., Faulds D. Lopinavir. Drugs 2000, 60:1371-1381.
112. Yamamoto N., Yang R., Yoshinaka Y., et al. HIV protease inhibitor nelfinavir inhibits replication of SARS-associated coronavirus. Biochem Biophys Res Commun 2004, 318:719-725.
113. Cinatl J., Morgenstern B., Bauer G., et al. Treatment of SARS with human interferons. Lancet 2003, 362:293-294.
114. Hensley L.E., Fritz L.E., Jahrling P.B., et al. Interferon-β 1a and SARS coronavirus replication. Emerg Infect Dis 2004, 10:317-319.
115. Sainz B., Mossel E.C., Peters C.J., et al. Interferon-beta and interferon-gamma synergistically inhibit the replication of severe acute respiratory syndrome-associated coronavirus (SARS-CoV). Virology 2004, 329:11-17.
116. Morgenstern B., Michaelis M., Baer P.C., et al. Ribavirin and interferon-beta synergistically inhibit SARS-associated coronavirus replication in animal and human cell lines. Biochem Biophys Res Commun 2005, 326:905-908.
117. Chen F., Chan K.H., Jiang Y., et al. In vitro susceptibility of 10 clinical isolates of SARS coronavirus to selected antiviral compounds. J Clin Virol 2005, 39:69-75.
118. Haagmans B.L., Kuiken T., Martina B.E., et al. Pegylated interferon-α protects type 1 pneumocytes against SARS coronavirus infection in macaques. Nat Med 2004, 10:290-293.
119. Loutfy M.R., Blatt L.M., Siminovitch K.A., et al. Interferon alfacon-1 plus corticosteroids in severe acute respiratory syndrome: a preliminary study. JAMA 2003, 290:3222-3228.
120. Sui J., Li W., Murakami A., et al. Potent neutralization of severe acute respiratory syndrome (SARS) coronavirus by a human mAb to S1 protein that blocks receptor association. Proc Natl Acad Sci U S A 2004, 101:2536-2541.
121. ter Meulen J., Bakker A.B., van den Brink E.N., et al. Human monoclonal antibody as prophylaxis for SARS coronavirus infection in ferrets. Lancet 2004, 363:2139-2141.
122. Gao W., Tamin A., Soloff A., et al. Effects of a SARS-associated coronavirus vaccine in monkeys. Lancet 2003, 362:1895-1896.
123. Zhao P., Ke J.S., Qin Z.L., et al. DNA vaccine of SARS-CoV S gene induces antibody response in mice. Acta Biochim Biophys Sin (Shanghai) 2004, 36:37-41.
124. Yang Z.Y., Kong W.P., Huang Y., et al. A DNA vaccine induces SARS coronavirus neutralization and protective immunity in mice. Nature 2004, 428:561-564.
125. Ho T.Y., Wu S.L., Cheng S.E., et al. Antigenicity and receptor-binding ability of recombinant SARS coronavirus spike protein. Biochem Biophys Res Commun 2004, 313:938-947.
126. Bisht H., Roberts A., Vogel L., et al. Severe acute respiratory syndrome coronavirus spike protein expressed by attenuated vaccinia virus protectively immunizes mice. Proc Natl Acad Sci U S A 2004, 101:6641-6646.
127. Bukreyev A., Lamirande E.W., Buchholz U.J., et al. Mucosal immunisation of African green monkeys (Cercopithecus aethiops) with an attenuated parainfluenza virus expressing the SARS coronavirus spike protein for the prevention of SARS. Lancet 2004, 363:2122-2127.
128. Bosch B.J., Martina B.E., van der Zee R., et al. Severe acute respiratory syndrome coronavirus (SARS-CoV) infection inhibition using spike protein heptad repeat-derived peptides. Proc Natl Acad Sci U S A 2004, 101:8455-8460.
129. Choy W.Y., Lin S.G., Chan P.K., et al. Synthetic peptide studies on the severe acute respiratory syndrome (SARS) coronavirus spike glycoprotein: perspective for SARS vaccine development. Clin Chem 2004, 50:1036-1042.
130. Ho J.C., Ooi G.C., Mok T.Y., et al. High dose pulse versus non-pulse corticosteroid regimens in severe acute respiratory syndrome. Am J Respir Crit Care Med 2003, 168:1449-1456.
131. Tsang O.T., Chau T.N., Choi K.W., et al. Coronavirus-positive nasopharyngeal aspirate as predictor for severe acute respiratory syndrome mortality. Emerg Infect Dis 2003, 9:1381-1387.
132. Wang H., Ding Y., Li X., et al. Fatal aspergillosis in a patient with SARS who was treated with corticosteroids. N Engl J Med 2003, 349:507-508.
133. Hong N., Du X.K. Avascular necrosis of bone in severe acute respiratory syndrome. Clin Radiol 2004, 59:602-608.
134. Griffith J.F., Antonio G.E., Kumta S.M., et al. Osteonecrosis of hip and knee in patients with severe acute respiratory syndrome treated with steroids. Radiology 2005, 235:168-175.
135. Lee N., Allen Chan K.C., Hui D.S., et al. Effects of early corticosteroid treatment on plasma SARS-associated Coronavirus RNA concentrations in adult patients. J Clin Virol 2004, 31:304-309.
136. Cheng Y., Wong R., Soo Y.O., et al. Use of convalescent plasma therapy in SARS patients in Hong Kong. Eur J Clin Microbiol Infect Dis 2005, 24:44-46.
137. Soo Y.O., Cheng Y., Wong R., et al. Retrospective comparison of convalescent plasma with continuing high-dose methylprednisolone treatment in SARS patients. Clin Microbiol Infect 2004, 10:676-678.
138. Liu B.Y., Hu J.Q., Xie Y.M., et al. Effects of integrative Chinese and Western medicine on arterial oxygen saturation in patients with severe acute respiratory syndrome. Chin J Integr Med 2004, 10:117-122.
139. Ballow M. Mechanisms of action of intravenous immune serum globulin in autoimmune and inflammatory diseases. J Allergy Clin Immunol 1997, 100:151-157.
140. Lew T.W., Kwek T.K., Tai D., et al. Acute respiratory distress syndrome in critically ill patients with severe acute respiratory syndrome. JAMA 2003, 290:374-380.
141. Chong P.Y., Chui P., Ling A.E., et al. Analysis of deaths during the severe acute respiratory syndrome (SARS) epidemic in Singapore: challenges in determining a SARS diagnosis. Arch Pathol Lab Med 2004, 128:195-204.
142. Umapathi T., Kor A.C., Venketasubramanian N., et al. Large artery ischaemic stroke in severe acute respiratory syndrome (SARS). J Neurol 2004, 251:1227-1231.
143. Ho J.C., Wu A.Y., Lam B., et al. Pentaglobulin in steroid-resistant severe acute respiratory syndrome. Int J Tuberc Lung Dis 2004, 8:1173-1179.
144. Ng K.H., Wu A.K., Cheng V.C., et al. Pulmonary artery thrombosis in a patient with severe acute respiratory syndrome. Postgrad Med J 2005, 81:e3.
145. Dalakas M.C., Clark W.M. Strokes, thromboembolic events, and IVIg: rare incidents blemish an excellent safety record. Neurology 2003, 60:1763-1767.
146. Chen L., Liu P., Gao H., et al. Inhalation of nitric oxide in the treatment of severe acute respiratory syndrome: a rescue trial in Beijing. Clin Infect Dis 2004, 39:1531-1535.
147. Akerstrom S., Mousavi-Jazi M., Klingstrom J., et al. Nitric oxide inhibits the replication cycle of severe acute respiratory syndrome coronavirus. J Virol 2005, 79:1966-1969.
148. WHO SARS case fatality ration, incubation period Available at:, Accessed May 23, 2005. http://www.who.int/csr/sars/archive/2003_05_07a/en/print.html.
149. Donnelly C.A., Ghani A.V., Leung G.M., et al. Epidemiological determinants of spread of causal agent of severe acute respiratory syndrome in Hong Kong. Lancet 2003, 361:1761-1766.
150. Tsui P.T., Kwok M.L., Yuen H., et al. Severe acute respiratory syndrome: clinical outcome and prognostic correlates. Emerg Infect Dis 2003, 9:1064-1069.
151. Chan J.W., Ng C.K., Chan Y.H., et al. Short term outcome and risk factors for adverse clinical outcomes in adults with Severe acute respiratory syndrome (SARS). Thorax 2003, 58:686-689.
152. Chu C.M., Poon L.L., Cheng V.C., et al. Initial viral load and the outcomes of SARS. CMAJ 2004, 171:1349-1352.
153. Hui D.S., Joynt G.M., Wong K.T., et al. Impact of severe acute respiratory syndrome (SARS) on pulmonary function, functional capacity and quality of life in a cohort of survivors. Thorax 2005, 60:401-409.
154. Hui D.S., Wong K.T., Ko F.W., et al. The one-year impact of severe acute respiratory syndrome (SARS) on pulmonary function, exercise capacity and quality of life in a cohort of survivors. Chest 2005, 128:2247-2261.
155. Tsai L.K., Hsieh S.T., Chao C.C., et al. Neuromuscular disorders in severe acute respiratory syndrome. Arch Neurol 2004, 61:1669-1673.
156. Yu W.C., Hui D.S., Chan-Yeung M. Antiviral agents and corticosteroids in the treatment of SARS. Thorax 2004, 59:643-645.
157. Tsang K.W., Ooi G.C., Ho P.L. Diagnosis and pharmacotherapy of severe acute respiratory syndrome: what have we learnt?. Eur Respir J 2004, 24:1025-1032.
158. Ong K.C., Ng A.W., Lee L.S., et al. 1-year pulmonary function and health status in survivors of severe acute respiratory syndrome. Chest 2005, 128:1393-1400.
159. Xie L., Liu Y., Xiao Y., et al. Follow-up study on pulmonary function and lung radiographic changes in rehabilitating severe acute respiratory syndrome patients after discharge. Chest 2005, 127:2119-2124.
160. Tansey C.M., Louie M., Loeb M., et al. One-year outcomes and health care utilization in survivors of severe acute respiratory syndrome. Arch Intern Med 2007, 167:1312-1320.
161. Chua S.E., Cheung V., McAlonan G.M., et al. Stress and psychological impact on SARS patients during the outbreak. Can J Psychiatry 2004, 49:385-390.
162. Cheng S.K., Wong C.W., Tsang J., et al. Psychological distress and negative appraisals in survivors of severe acute respiratory syndrome (SARS). Psychol Med 2004, 34:1187-1195.
163. Lee D.T., Wing Y.K., Leung H.C., et al. Factors associated with psychosis among patients with severe acute respiratory syndrome: a case-control study. Clin Infect Dis 2004, 39:1247-1249.
164. Chen Z., Zhang L., Qin C., et al. Recombinant modified vaccinia virus Ankara expressing the spike glycoprotein of severe acute respiratory syndrome coronavirus induces protective neutralizing antibodies primarily targeting the receptor binding region. J Virol 2005, 79:2678-2688.
165. He Y., Li J., Heck S., et al. Antigenic and immunogenic characterization of recombinant baculovirus-expressed severe acute respiratory syndrome coronavirus spike protein: implication for vaccine design. J Virol 2006, 80:5757-5767.
166. Weingartl H., Czub M., Czub S., et al. Immunization with modified vaccinia virus Ankara-based recombinant vaccine against severe acute respiratory syndrome is associated with enhanced hepatitis in ferrets. J Virol 2004, 78:12672-12676.
167. Petersen N.C., Boyle J.F. Immunologic phenomena in the effusive form of feline infectious peritonitis. Am J Vet Res 1980, 41:868-876.
168. Vennema H., de Groot R.J., Harbour D.A., et al. Early death after feline infectious peritonitis virus challenge due to recombinant vaccinia virus immunization. J Virol 1990, 64:1407-1409.
169. Chan P.K., Ip M., Ng K.C., et al. Severe acute respiratory syndrome-associated coronavirus infection. Emerg Infect Dis 2003, 9:1453-1454.